Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14041198 | 0.86 | MAPT (0.40) | MAPTIDO1TDO2 | |
| SCHEMBL13063080 | 0.83 | MAPT (0.39) | MAPTIDO1TDO2 | |
| SCHEMBL13542717 | 0.77 | MAPT (0.43) | MAPT | |
| SCHEMBL14279199 | 0.76 | MAPT (0.46) | MAPTIDO1TDO2 | |
| SCHEMBL13479444 | 0.76 | MAPT (0.46) | MAPTIDO1TDO2 | |
| SCHEMBL19231532 | 0.76 | MAPT (0.46) | MAPTIDO1TDO2 | |
| SCHEMBL11223105 | 0.75 | MAPT (0.45) | MAPTIDO1TDO2 | |
| SCHEMBL11028267 | 0.75 | MAPT (0.45) | MAPTIDO1TDO2 | |
| SCHEMBL14494221 | 0.74 | MAPT (0.40) | MAPTIDO1TDO2 | |
| SCHEMBL16389606 | 0.74 | MAPT (0.35) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1448517-B1 | METHOD OF PREPARING 4-CHLORO-3-METHYL-2-BUTENYLPHENYL SULFIDE, DI(4-CHLORO-3-METHYL-2-BUTENYL)SULFIDE AND DI(4-CHLORO-3-METHYL-2-BUTENYL)SULFONE FOR SYNTHESIS OF NATURAL CAROTENOID PRODUCTS | SK INNOVATION CO LTD (KR) | 2012-04-18 | — | — | EP | disclosed |
| US-8063101-B2 | Carotenoid analogs and derivatives for the prevention of platelet aggregation | CARDAX PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20090124574-A1 | Carotenoid analogs and derivatives for the prevention of platelet aggregation | CARDAX PHARMA, INC. | 2009-05-14 | — | — | US | disclosed |
| US-20070238793-A1 | Structural carotenoid analogs or derivatives for the modulation of systemic and/or target organ redox status | CARDAX PHARMACEUTICALS, INC. | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238793-A1 | Structural carotenoid analogs or derivatives for the modulation of systemic and/or target organ redox status | LPO, TXN2, TXNRD2 | MAPT 3121/4885IDO1 617/4885TDO2 125/4885 |
| US-20090124574-A1 | Carotenoid analogs and derivatives for the prevention of platelet aggregation | PROC, PFKP, PF4 | MAPT 4493/4885IDO1 2503/4885TDO2 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.